Unitree disclosed its first quarterly report since going public: Q3 revenue grew approximately 70% year-over-year, while net profit declined by about 17.4% year-over-year. The company stated that the drop in profit was related to increased investment in embodied AI models, computing power, and research personnel.
On October 28, Unitree Robotics and Sequoia China announced the establishment of the "Shanyu Innovation Program," dedicated to discovering and investing in early-stage startups in embodied intelligence, robotics applications, and key upstream and downstream technologies. Official statements indicate that this program combines Unitree's engineering capabilities with Sequoia's investment expertise, using an "Engineer + Investor" methodology to provide early entrepreneurs with technical, production line, and financial resources.
The successive disclosure of these two pieces of information has brought Unitree's three strategic lines—"commercialization of robot bodies, R&D investment in AI, and industrial capital deployment"—into the public spotlight simultaneously.
01Quarterly Structure: Coexistence of Revenue Growth and Profit Decline
Unitree's key financial data for Q3 is as follows:
Note: The Q2 net profit attributable to parent company shareholders of CNY 224 million and the Q3 quarter-over-quarter decline were calculated based on quarterly report data; the company did not directly disclose the quarter-over-quarter metric.
Based on the above data, Unitree experienced simultaneous revenue growth and profit decline in Q3, accompanied by a significant year-over-year increase in R&D expenses. The explanation provided in the quarterly report is that there was substantial growth in model development and computing power investment related to large embodied models, along with expansion of the R&D team and initiation of new product development. In other words, the profit decline corresponds to a clear rise in R&D investment. Whether this constitutes "actively trading profits for growth" remains to be seen; while the company attributes it to increased R&D spending, the return on investment still needs verification in subsequent quarters.
Wang Xingxing previously reflected that his biggest mistake was "not believing enough in AI," which led him to advance the timeline for scaling humanoid robots. This statement serves as background context for understanding Unitree's increased AI investment but should not be directly equated with a complete explanation for single-quarter profit fluctuations.
02Shanyu Program: Joint Early-Stage Investment by Robot Body Manufacturer and VC
This program is jointly initiated by Unitree and Sequoia China, targeting early-stage projects in embodied intelligence, robotics applications, and key upstream and downstream technologies. It provides technical, production line, and financial resources through an "Engineer + Investor" methodology. This is not the first collaboration between Sequoia China and Unitree—the Sequoia Seed Fund participated in Unitree's Pre-A round investment and continued to support subsequent rounds.
From publicly available information, this program places the engineering and production line resources of a body manufacturer alongside the capital and post-investment capabilities of a VC within the same early-stage investment framework. For early-stage projects, technical judgment, engineering experience from prototype to mass production, and supply chain resources represent incremental capabilities offered by body manufacturers compared to VCs. For Unitree, participating in early-stage projects may also enhance its understanding of upstream and downstream technology roadmaps and application scenarios.
The Shanyu Program reflects an attempt by leading body manufacturers to participate in early-stage ecosystem building through industrial capital. It extends Unitree's involvement from body products forward to early-stage projects, but whether this constitutes a fundamental change in competitive logic requires observation of its actual investment portfolio, synergy cases, and returns.
03Increase in External Investments by Body Manufacturers, But Strategic Effectiveness Remains to Be Verified
Viewing Unitree in the industry context, external investments by body manufacturers are not isolated incidents.
According to public reports, AgiBot has invested in multiple early-stage projects over the past period and jointly established an embodied intelligence industry fund with Hillhouse Investment. Its external investments cover motors, sensors, drivers, materials, large models, body development, and application scenarios. Leju Robotics also invested in upstream and downstream companies such as Quanzhibo, Liju Power, LinkerBot, Junaopanshi, and Jushi Intelligent during its Pre-IPO stage. Multiple body manufacturers making external investments indicates rising participation of industrial capital in early-stage embodied intelligence projects.
However, the number of investments cannot be directly equated with strategic effectiveness. When body manufacturers engage in early-stage investments, they may gain insights into technology roadmaps and achieve ecosystem synergies, but they may also face practical issues regarding the allocation of energy between core business and investments, implementation of post-investment resources, and investment return cycles.
04Stock Price Rebound vs. Profit Decline: Divergent Market Interpretations
Unitree's market cap rebounded after hitting a staged low, increasing by approximately CNY 108 billion to CNY 271.8 billion over seven trading days. During the same period, Wang Xingxing's statements regarding the timeline for physical AI attracted market attention; JPMorgan upgraded its rating from "Underweight" by two levels to "Overweight," citing reasons including the potential advancement of the "adoption curve" for physical AI. It should be noted that stock prices are influenced by multiple factors, and the rebound cannot be simply attributed to a single statement or one quarter's earnings report.
Market interpretations of Unitree's "profit decline" also diverge. One view holds that increased R&D investment is a necessary phase-specific expenditure for embodied intelligence enterprises; another view suggests that profit pullbacks and valuation fluctuations indicate remaining uncertainties in commercialization landing and R&D returns. In its announcement regarding abnormal stock price movements, Unitree also cautioned that the humanoid robot industry is still in the early stages of commercialization, and the transition of physical AI from laboratory to scaled implementation faces challenges in perception accuracy, motion control stability, data accumulation, and software-hardware coordination. If progress falls short of expectations, there is a risk of valuation regression.
Therefore, a more objective observation is that Unitree's current valuation includes both support from body mass production and revenue growth, as well as expectations for enhanced embodied AI capabilities. The profit decline itself does not constitute sufficient evidence of weakened competitiveness, but whether R&D investment can form sustainable product and revenue returns still requires verification through subsequent financial reports and business progress.
Conclusion
Unitree is currently advancing three lines simultaneously: commercialization of robot bodies, R&D investment in embodied AI, and industrial capital deployment. The first quarterly report shows coexistence of revenue growth and profit decline, with significantly increased R&D investment; the Shanyu Program demonstrates Unitree's participation in early-stage project investments through joint ventures with VCs.
These two pieces of information collectively reflect a shift in its strategic focus from single-body sales to an expansion encompassing "Body + AI R&D + Industrial Capital." However, the actual effectiveness of this expansion still needs to be tested through subsequent financial data, investment portfolios, and synergy cases.